• Explore /
  • Poster
  • / Optimizing PD-L1 as a biomarker of response with pembrolizumab (pembro; MK-3475) as first-line therapy for PD-L1–positive metastatic non-small cell lung cancer (NSCLC): Updated data from KEYNOTE-001.

Optimizing PD-L1 as a biomarker of response with pembrolizumab (pembro; MK-3475) as first-line therapy for PD-L1–positive metastatic non-small cell lung cancer (NSCLC): Updated data from KEYNOTE-001.

Abstract Poster

Authors

null

Naiyer A. Rizvi

Columbia University Medical Center, New York, NY

Naiyer A. Rizvi , Edward B. Garon , Natasha Leighl , Matthew David Hellmann , Amita Patnaik , Leena Gandhi , Joseph Paul Eder , Reshma A. Rangwala , Gregory Lubiniecki , Jin Zhang , Kenneth Emancipator , Charlotte M. Roach , Ruth Rutledge , Rina Hui , Myung-Ju Ahn , Leora Horn , Enriqueta Felip , Enric Carcereny Costa

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT01295827

Citation

J Clin Oncol 33, 2015 (suppl; abstr 8026)

DOI

10.1200/jco.2015.33.15_suppl.8026

Abstract #

8026

Poster Bd #

348

Abstract Disclosures

Similar Posters

First Author: Panpan Zhang

First Author: Christos Chouaid

First Author: Marina Chiara Garassino

First Author: Julie R. Brahmer